NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 13:30
Last Report Issued 01/20/2014 13:20

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 4366B
Patient ID 4366B
Chain 14000172
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 14000172

Received 01/20/2014 12:31

Sample ID 14000172-001
Matrix Blood
Patient Name 4366B
Patient ID 4366B
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
4366B Teriflunomide (Therapeutic Drug Monitoring), Blood				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Teriflunomide	None Detected	ng/mL	500	

Synonym(s): Aubagio®

Teriflunomide is indicated for the treatment of patients with relapsing forms of multiple sclerosis. It takes approximately 3 months to reach steady-state concentrations.

Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL. The blood to plasma ratio is 0.5 to 0.7.

Following completion of an elimination regimen, plasma

Results for sample 14000172-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 14000172-001
Matrix Blood
Patient Name 4366B
Patient ID 4366B

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. THIS TEST IS NOT MEANT TO MONITOR THE ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING POTENTIAL WHO DISCONTINUE TERIFLUNOMIDE. The drug carries a black box warning for hepatotoxicity and teratogenicity.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.